Omalizumab biosimilar is under clinical development by Kashiv BioSciences and currently in Phase III for Chronic Urticaria Or Hives. According to GlobalData, Phase III drugs for Chronic Urticaria Or Hives have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Omalizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Omalizumab biosimilar overview
Omalizumab biosimilar is under development for the treatment of Asthma, chronic idiopathic urticaria. It is developed based on MayaBio reactor technology. The drug candidate is administered through subcutaneous route. It acts by targeting immunoglobulin E.
Kashiv BioSciences overview
Kashiv BioSciences (Kashiv) is a biopharmaceutical company. Its product pipeline includes RELEUKO, FYLNETRA, ADL-018, KSHB001 and KSHB002.The company’s pipeline treats oncology, immunology, respiratory and digestive care. Kashiv also carries out the mRNA platform. It provides services such as formulation development, analytical development, and clinical supply manufacturing. The company also offers contract research and development services to the pharmaceutical sector. It operates a research and development facility in the US. Kashiv is headquartered in Bridgewater, New Jersey, the US.
For a complete picture of Omalizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
